

**FORM PTO-1449**  
**INFORMATION DISCLOSURE STATEMENT**

**ATTORNEY DOCKET NO.**  
**P33027USW**

INTL. SERIAL NO.  
PCT/EP03/0366Y

**APPLICANT: Giblin et al.**

**INTL. FILING DATE:**  
April 7, 2003

**GROUP**

## U.S. PATENT DOCUMENTS

[illegible]

**Continue on page**

## FOREIGN PATENT DOCUMENTS

[illegible]

**Continue on page**

**OTHER DOCUMENTS (Including Author, Title, Journal-Date, Page Number, Etc.)**

[illegible]

**Continue on page**

**EXAMINER**

**/Binta Robinson/**

DATE CONSIDERED \_\_\_\_\_

08/17/2006

**EXAMINER:** Initial if citation considered, whether or not citation is in conformance with MPEP § 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to the applicant.

Sheet 1 of 2

Form PTO-1449	U.S. Department of Commerce Patent and Trademark Office	ATTY DOCKET NO. P33027USW	SERIAL NO. 10/508,761
<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b> (Use several sheets if necessary)		APPLICANT Giblin et al.	
		FILING DATE Sept. 22, 2004	GROUP 1625

## U.S. PATENT DOCUMENTS

Examiner Initials	Document Number	Date	Name	Class	Subclass	Filing Date If Appropriate

## FOREIGN PATENT DOCUMENTS

Examiner Initials	Document Number	Date	Country	Class	Subclass	Translation Yes No
BML	EP-03/03561	4/15/93	EP			

## OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc)

BML	2	AHMAD, ET AL.; Prostaglandin EP1 Receptor Contributes to Excitotoxicity and Focal Ischemic Brain Damage; Toxicological Sciences; October 19, 2005; 69(1): 265-270; Oxford University Press;
BML	3	KAWAHARA, ET AL.; A Prostaglandin E2 Receptor Subtype EP1 Receptor Antagonist (ONO-8711) Reduces Hyperalgesia, Allodynia, and C-fos Gene Expression in Rats with Chronic Nerve Constriction; Anesth Analg; 2001; 93: 1012-7; International Anesthesia Research Society;
BML	4	KAWANO, ET AL.; Prostaglandin E2 EP1 Receptors: Downstream Effectors of Cox-2 Neurotoxicity; Nature Medicine; February 2005; 12(2): 225-229; Nature Publishing Group;
BML	5	OMOTE, ET AL.; The Effects of Intrathecal Administration of an Antagonist for Prostaglandin E Receptor Subtype EP1 on Mechanical and Thermal Hyperalgesia in a Rat Model of Postoperative Pain; Anesth Analg; 2002; 95: 1708-12; International Anesthesia Research Society;
BML	6	OMOTE, ET AL.; The Effects of Peripheral Administration of a Novel Selective Antagonist for Prostaglandin E Receptor Subtype EP1, ONO-8711, in a Rat Model of Postoperative Pain; Anesth Analg; 2001; 92: 233-6; International Anesthesia Research Society;
	7	SARKAR, ET AL.; The Prostaglandin E2 Receptor-1 (EP1) Mediates Acid-Induced Visceral Pain Hypersensitivity in Humans; Gastroenterology; 2003; 124: 18-25; American Gastroenterological Association;

Examiner Signature <i>Bento Robinson</i>	Date Considered 1/26/07
EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.	

Sheet 2 of 2

Form PTO-1449	U.S. Department of Commerce Patent and Trademark Office	ATTY DOCKET NO. P33027USW	SERIAL NO. 10/506,761
<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b> <i>(Use several sheets if necessary)</i>		APPLICANT Giblin et al.	
		FILED DATE Sept. 22, 2004	GROUP 1625

## U.S. PATENT DOCUMENTS

Examiner Initials	Document Number	Date	Name	Class	Subclass	Filing Date If Appropriate

## FOREIGN PATENT DOCUMENTS

	Document Number	Date	Country	Class	Subclass	Translation Yes No

## OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc)

BR		
6	STOCK, ET AL.: The Prostaglandin E2 EP1 Receptor Mediates Pain Perception and Regulates Blood Pressure; The Journal of Clinical Investigation; February 2001; 107(3): 325-331;	

Examiner Signature /Binta Robinson/	Date Considered 01/26/2007
EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.	

FORM PTO-1449 INFORMATION DISCLOSURE STATEMENT APR 25 2005 PATENT & TRADEMARK OFFICE				SERIAL NO. 10/508,761 FILING DATE September 22, 2004 APPLICANT Giblin et al. GROUP 1615 EXAMINER ATTORNEY DOCKET NO. P33027USW			
U.S. PATENT DOCUMENTS							
Examiner Initials		Patent Number	Issue Date	Name	Class	Subclass	Filing Date If Appropriate
BML	1	6,495,149	Dec. 17, 2002	Scavone et al.			
	2	6,440,963	Aug. 27, 2002	Leonardi et al.			
	3	US 2002 045605	Apr. 18, 2002	Kargman et al.			
	4	6,136,839	Oct. 24, 2000	Isakson et al.			
	5	5,972,986	Oct. 26, 1999	Seibert et al.			
	6	5,840,746	Nov. 24, 1998	Ducharme et al.			
	7	5,663,180	Sept. 2, 1997	Reitz et al.			
	8	5,474,995	Dec. 12, 1995	Ducharme et al.			
	9	5,344,991	Sept. 6, 1994	Reitz et al.			
	10	5,420,287	May 30, 1995	Reitz, et al.			
Continue on page 2							
FOREIGN PATENT DOCUMENTS							
		Document Number	Publication Date	Country	Class	Subclass	Translation Yes   No
BML	13	EP 1264847	Dec. 11, 2002	EUROPE			Abstract only
BML	14	JP 2002363748	Dec. 18, 2002	JAPAN			Abstract only
BML	15	WO 02/099435	Dec. 12, 2002	WIPO			
BML	16	EP 1251126	Oct. 23, 2002	EUROPE			
BML	17	WO 01/081332	Nov. 1, 2001	WIPO			
BML	18	WO 00/53149	Sept. 14, 2000	WIPO			
BML	19	WO 00/47553	Aug. 17, 2000	WIPO			
BML	20	WO 99/58487	Nov. 19, 1999	WIPO			
BML	21	WO 99/17776	Apr. 15, 1999	WIPO			
BML	22	WO 98/55468	Dec. 10, 1998	WIPO			
BML	23	WO 98/16227	Apr. 23, 1998	WIPO			
BML	24	WO 97/16435	May 9, 1997	WIPO			
BML	25	WO 97/11701	Apr. 3, 1997	WIPO			
BML	26	WO 97/03667	Feb. 6, 1997	WIPO			
BML	27	WO 96/41645	Dec. 27, 1996	WIPO			
BML	28	WO 96/36623	Nov. 21, 1996	WIPO			
BML	29	WO 96/11676	Apr. 25, 1996	WIPO			
BML	30	WO 95/00501	Jan. 5, 1995	WIPO			
BML	31	WO 95/17393	June 29, 1995	WIPO			
BML	32	WO 95/05372	Feb. 23, 1995	WIPO			
Continue on page 2							
OTHER DOCUMENTS (Including Author, Title, Journal-Date, Page Number, Etc.)							
BML	58	Whitesell, J.K., et al. "Synthesis and Resolution of a New Chiral C2-Symmetric Bisphenol: Trans-1,2-Bis(2-Hydroxyphenyl)cyclopentane." Tetrahedron Letters, 1997, 38(15), pgs. 2589-2592.					
BML	59	Rathore, R., et al. "Efficient Hydrogenation of Sterically Hindered Olefins with Borane-Methyl Sulfide Complex." Journal of Organic Chemistry, 1996, 61(16), pgs. 5246-5256.					
BML	60	Malik, O.P., et al. "Studies on Cannabinoids: Part III. Synthesis of 9,10,11,11a-Tetrahydro-6H,8H-Pyrido[1,2-c][1,3]benzoxazine." Indian Journal of Chemistry, Section B: Organic Chemistry Including Medicinal Chemistry, 1976, 14B(12), pgs 975-978.					
Continue on page							
EXAMINER <i>[Signature]</i>					DATE CONSIDERED 8/17/06		
EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP § 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to the applicant.							

FORM PTO-1449 INFORMATION DISCLOSURE STATEMENT				SERIAL NO.		10/508,761	
				FILING DATE		September 22, 2004	
				APPLICANT		Giblin et al.	
				GROUP		1615	
				EXAMINER			
				ATTORNEY DOCKET NO.		P33027USW	
U.S. PATENT DOCUMENTS							
Examiner Initials		Patent Number	Issue Date	Name	Class	Subclass	Filing Date If Appropriate
BWL	11	5,512,681	Apr. 30, 1996	Boswell et al.			
BWL	12	5,424,450	June 13, 1995	Boswell et al.			
Continue on page							
FOREIGN PATENT DOCUMENTS							
		Document Number	Publication Date	Country	Class	Subclass	Translation Yes   No
BWL	33	GB 2,272,899	June 1, 1994	GREAT BRITAIN			
BWL	34	JP 06065213	March 8, 1994	JAPAN			Abstract only
BWL	35	JP 05224442	Sept. 3, 1993	JAPAN			Abstract only
BWL	36	EP 540009	May 5, 1993	EUROPE			
BWL	37	JP 04076087	March 10, 1992	JAPAN			Abstract only
BWL	38	DE 4034728	May 7, 1992	GERMANY			Abstract only
BWL	39	DE 4032522	Apr. 16, 1992	GERMANY			Abstract only
BWL	40	WO 97/38986	Oct. 23, 1997	WIPO			
BWL	41	WO 95/11883	May 4, 1995	WIPO			
BWL	42	WO 96/37496	Nov. 28, 1996	WIPO			
BWL	43	WO 94/05658	Mar. 17, 1994	WIPO			
BWL	44	JP 04235933	Aug. 25, 1992	JAPAN			Abstract only
BWL	45	EP 131302	Jan. 16, 1985	EUROPE			
BWL	46	AU 8311483	Mar. 3, 1982	AUSTRALIA			Abstract only
BWL	47	EP 52300	Nov. 13, 1980	EUROPE			Abstract only
BWL	48	DT 2405171	Feb. 19, 1973	GERMANY			Abstract only
BWL	49	NE 6610022	Aug. 2, 1965	NIGER			Abstract only
BWL	50	BEL 611179	Dec. 6, 1960	BELGIUM			X
BWL	51	DE 20211496	Nov. 19, 2002	GERMANY			Abstract only
BWL	52	WO 98/25896	June 18, 1998	WIPO			
BWL	53	EP 0799823	Oct. 8, 1997	EUROPE			
BWL	54	WO 01/19814	Mar. 22, 2001	WIPO			
BWL	55	WO 93/04045	Mar. 4, 1993	WIPO			
BWL	56	WO 93/04046	Mar. 4, 1993	WIPO			
BWL	57	WO 00/59506	Oct. 12, 2000	WIPO			
Continue on page							
OTHER DOCUMENTS (Including Author, Title, Journal-Date, Page Number, Etc.)							
EXAMINER				DATE CONSIDERED			
BWL				8/16/06			
EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP § 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to the applicant.							

1 P6107